Cargando…
Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial
Identification of new medications for alcohol use disorder (AUD) is important for improving treatment options. Baclofen, a GABA(B) agonist, has been identified as a potential pharmacotherapy for AUD. In a 16-week double-blind, randomized, placebo-controlled trial, we investigated 30 and 90 mg/day of...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580979/ https://www.ncbi.nlm.nih.gov/pubmed/34155332 http://dx.doi.org/10.1038/s41386-021-01055-w |